NASDAQ:IRD Opus Genetics (IRD) Stock Price, News & Analysis $1.07 -0.02 (-1.83%) Closing price 04:00 PM EasternExtended Trading$1.06 -0.01 (-0.47%) As of 07:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock About Opus Genetics Stock (NASDAQ:IRD) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Opus Genetics alerts:Sign Up Key Stats Today's Range$1.05▼$1.1050-Day Range$0.91▼$1.2252-Week Range$0.65▼$1.77Volume59,766 shsAverage Volume558,795 shsMarket Capitalization$63.84 millionP/E RatioN/ADividend YieldN/APrice Target$7.33Consensus RatingBuy Company Overview Opus Genetics Inc. is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc., formerly known as Ocuphire Pharma Inc., is based in Farmington Hills, Michigan. Read More Opus Genetics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks26th Percentile Overall ScoreIRD MarketRank™: Opus Genetics scored higher than 26% of companies evaluated by MarketBeat, and ranked 818th out of 923 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingOpus Genetics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageOpus Genetics has only been the subject of 1 research reports in the past 90 days.Read more about Opus Genetics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Opus Genetics are expected to grow in the coming year, from ($1.22) to ($1.03) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Opus Genetics is -0.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Opus Genetics is -0.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioOpus Genetics has a P/B Ratio of 5.10. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Opus Genetics' valuation and earnings. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for IRD. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldOpus Genetics does not currently pay a dividend.Dividend GrowthOpus Genetics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Short InterestThere is no current short interest data available for IRD. News and Social Media0.6 / 5News Sentiment0.00 News Coverage This WeekMarketBeat has tracked 2 news articles for Opus Genetics this week, compared to 1 article on an average week.Search Interest2 people have searched for IRD on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Opus Genetics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 6.60% of the stock of Opus Genetics is held by insiders.Percentage Held by InstitutionsOnly 14.97% of the stock of Opus Genetics is held by institutions.Read more about Opus Genetics' insider trading history. Receive IRD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Opus Genetics and its competitors with MarketBeat's FREE daily newsletter. Email Address IRD Stock News HeadlinesOpus Genetics to Participate in the H.C. Wainwright 5th Annual Ophthalmology Virtual ConferenceAugust 5 at 8:00 AM | globenewswire.comOpus Genetics and the Global RDH12 Alliance Partner to Advance RDH12 Gene Therapy for Inherited Childhood BlindnessJuly 24, 2025 | finance.yahoo.comAmazon’s big Bitcoin embarrassmentBitcoin just passed Amazon in total market cap — but most investors are missing the bigger opportunity. While the crowd buys Bitcoin outright, trader Larry Benedict is using a method called “Bitcoin Skimming” to target 6x, 9x, even 22x bigger profits. He reveals how it works in a free video.August 8 at 2:00 AM | Brownstone Research (Ad)Opus Genetics and the Global RDH12 Alliance Partner to Advance RDH12 Gene Therapy for Inherited Childhood BlindnessJuly 23, 2025 | globenewswire.comOpus Genetics Announces Inducement Grants Under Nasdaq Listing Rule 5635 (c) (4) - MorningstarJuly 5, 2025 | morningstar.comMOpus Genetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)July 3, 2025 | globenewswire.comOpus Genetics, Inc. (IRD) Income Statement - Yahoo FinanceJune 30, 2025 | finance.yahoo.comOpus Genetics Announces VEGA-3 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% for the Treatment of PresbyopiaJune 26, 2025 | globenewswire.comSee More Headlines IRD Stock Analysis - Frequently Asked Questions How have IRD shares performed this year? Opus Genetics' stock was trading at $1.19 at the start of the year. Since then, IRD shares have decreased by 10.1% and is now trading at $1.07. How were Opus Genetics' earnings last quarter? Opus Genetics, Inc. (NASDAQ:IRD) released its quarterly earnings data on Thursday, May, 15th. The company reported ($0.32) earnings per share for the quarter, beating the consensus estimate of ($0.34) by $0.02. The business had revenue of $4.30 million for the quarter, compared to the consensus estimate of $4 million. Opus Genetics had a negative net margin of 429.42% and a negative trailing twelve-month return on equity of 283.28%. How do I buy shares of Opus Genetics? Shares of IRD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings5/15/2025Today8/08/2025Next Earnings (Estimated)8/12/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:IRD Previous SymbolNASDAQ:IRD CIK1228627 Webwww.ocuphire.com Phone248-957-9024Fax240-268-5310Employees14Year FoundedN/APrice Target and Rating Average Price Target for Opus Genetics$7.33 High Price Target$8.00 Low Price Target$6.00 Potential Upside/Downside+585.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($2.10) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$57.53 million Net Margins-429.42% Pretax Margin-429.42% Return on Equity-283.28% Return on Assets-144.32% Debt Debt-to-Equity RatioN/A Current Ratio1.98 Quick Ratio1.98 Sales & Book Value Annual Sales$10.99 million Price / Sales5.81 Cash FlowN/A Price / Cash FlowN/A Book Value$0.21 per share Price / Book5.10Miscellaneous Outstanding Shares59,660,000Free Float55,723,000Market Cap$63.84 million OptionableN/A Beta0.01 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for August 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free Report This page (NASDAQ:IRD) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersAmazon’s big Bitcoin embarrassmentBitcoin just passed Amazon in total market cap — but most investors are missing the bigger opportunity. Whi...Brownstone Research | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredFormer CIA Officer Reveals How Gold Saved His Life This isn’t just another gold investing book—it’s a survival playbook written by a former CIA officer trained...Advantage Gold | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredHow high will gold surge?Weiss Gold Veteran Makes Shocking New Call Weiss expert Sean Brodrick went out on a limb last year and decl...Weiss Ratings | SponsoredShocked one of my clients with thisTrump Schedules Controversial 'Market Reset' for September 30 Behind closed doors, the White House has orde...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Opus Genetics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Opus Genetics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.